$CNTB 8-K SEC Filings

Filed On	Filing
30 Sep 2026	8-K: Regulation FD Disclosure; Other Events Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation
15 Sep 2026	8-K: Regulation FD Disclosure; Other Events Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adult and Adolescent Participants with Asthma and Type 2 Inflammation
12 Aug 2026	8-K: Results of Operations and Financial Condition
12 May 2026	8-K: Results of Operations and Financial Condition
23 Apr 2026	8-K: Regulation FD Disclosure; Other Events
31 Mar 2026	8-K: Results of Operations and Financial Condition
30 Mar 2026	8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +2 more
23 Dec 2025	8-K: Departure/Election of Directors or Officers; Compensation
12 Nov 2025	8-K: Results of Operations and Financial Condition
16 Sep 2025	8-K: Regulation FD Disclosure
13 Aug 2025	8-K: Results of Operations and Financial Condition
22 Jul 2025	8-K: Departure/Election of Directors or Officers; Compensation
21 Jul 2025	8-K: Termination of a Material Definitive Agreement
17 Jul 2025	8-K: Other Events
09 Jul 2025	8-K: Regulation FD Disclosure; Other Events
15 May 2025	8-K: Results of Operations and Financial Condition
14 May 2025	8-K: Regulation FD Disclosure; Other Events
13 May 2025	8-K: Regulation FD Disclosure; Other Events
01 Apr 2025	8-K: Regulation FD Disclosure; Other Events
31 Mar 2025	8-K: Results of Operations and Financial Condition

Comments